Principles of Melanoma Staging

Area of Science:

• Oncology
• Dermatology
• Cancer Biology

Background:

• Cancer staging systems are crucial for characterizing disease status, risk stratification, prognostication, and clinical decision-making.
• The American Joint Committee on Cancer (AJCC) melanoma staging system has undergone significant revisions reflecting advancements in understanding melanoma biology.

Purpose of the Study:

• To review the evolution of the AJCC melanoma staging system.
• To highlight key changes in melanoma staging criteria over time.
• To discuss the integration of clinicopathological and molecular factors for future staging refinement.

Main Methods:

• Review of historical and current AJCC melanoma staging editions.
• Analysis of changes in clinicopathological variables used for staging.
• Examination of the impact of new diagnostic techniques on staging.

Main Results:

• Early staging relied on tumor thickness (Breslow) and anatomical depth (Clark level).
• Regional nodal basin management evolved with sentinel lymph node biopsy (SLNB).
• Distant metastasis stratification now includes anatomic site and serum lactate dehydrogenase levels.

Conclusions:

• Current AJCC staging variables are validated survival outcome predictors.
• Future melanoma staging will likely integrate molecular and biological correlates for personalized approaches.
• Continued refinement of staging systems is essential for optimal melanoma patient care.